Heart attack diagnostics market is set to reach US$ 18.5 billion by 2030, at a CAGR of 8.6% . North America leads the market with 43% market share.

The global heart attack diagnostics market size was estimated at USD 11.5 billion in 2024 and is projected to reach USD 18.5 billion by 2030, growing at a CAGR of 8.6% from 2025 to 2030. Unhealthy lifestyle choices, such as poor dietary habits, tobacco smoking, high body mass index, sedentary lifestyles, and the prevalence of chronic diseases such as diabetes and hypertension, are the primary risk factors contributing to the development of heart attacks in individuals.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):-https://www.datamintelligence.com/download-sample/heart-attack-diagnostics-market?prtk

United States: Key Industry Developments (2026 & 2025)

✅ January 2026: Heartbeam's 12‐lead mobile ECG system achieved a limited commercial rollout targeting concierge and preventive cardiology groups in the U.S., expanding advanced pre‐hospital ECG diagnostics beyond traditional hospital settings.

✅ March 2025 (Product Launch): Roche Diagnostics received FDA 510(k) clearance for an enhanced Elecsys® Troponin T high‐sensitivity test, aimed at delivering more precise risk stratification and rapid detection for patients presenting with chest pain in emergency departments.

✅ April 2025 (Product Launch): Siemens Healthineers launched the Atellica® CI1900 Integrated Solution in the U.S., combining core and cardiac lab testing to consolidate troponin diagnostics into a single high‐throughput platform, improving workflow and throughput for acute cardiac care.

✅ March 2025 (Clinical Development): Abbott Laboratories initiated a major clinical study across 100 U.S. and European sites to expand clinical claims for its Alinity i High‐Sensitivity Troponin‐I assay, focusing on rapid rule‐out protocols to reduce ER congestion and improve early myocardial infarction management.

Japan: Key Industry Developments ( 2026 & 2025)

✅ November 2025 (Product Focus): Roche introduced a new AI‐enhanced cardiac biomarker test in Japan, leveraging advanced algorithms to improve diagnostic precision in heart attack assessment and support clinician decision workflows.

✅ August 2025 (Strategic Development): Siemens Healthineers expanded its cardiac point‐of‐care biomarker diagnostics portfolio in Japan via a strategic acquisition of a POC diagnostics startup, strengthening rapid heart attack testing solutions across local healthcare providers.

Recent M&A activities:-

→ In January 2026, Boston Scientific agreed to acquire Penumbra in a deal valued at $14.5 billion. This acquisition significantly expands Boston Scientific's cardiovascular device and diagnostic portfolio, including products relevant to heart attack and acute cardiovascular event management. The deal is expected to close later in 2026 and will be financed with a combination of cash and stock.

→ In September 2025, Novartis agreed to acquire Tourmaline Bio for approximately $1.4 billion ($48 per share). Tourmaline's lead asset, pacibekitug, is a monoclonal antibody in development for atherosclerotic cardiovascular disease (ASCVD) a key contributor to heart attacks and the acquisition strengthens Novartis's cardiovascular and diagnostics/therapeutic portfolio. The transaction was expected to complete in Q4 2025.

→ In September 2025, Edwards Lifesciences completed the full acquisition of Vectorious Medical Technologies a cardiovascular diagnostics and heart monitoring technology company in a transaction valued at approximately $497 million. Vectorious's technology focuses on cardiac pressure monitoring (important for heart failure and cardiovascular risk) and bolsters Edwards's diagnostic/monitoring capabilities.

Key Players:-

F Hoffmann-La Roche Ltd, Hitachi Medical Systems, GE Healthcare, Schiller AG, Siemens Healthineers, HeartFlow, Beckman Coulter, Medtronic, Cardio Diagnostics Holdings Inc, and Midmark Corporation, among others.

Top 5 Key Players Analysis:-

F. Hoffmann‐La Roche Ltd. - Leading with 23.1% share driven by high‐sensitivity cardiac biomarker assays and broad global diagnostics reach.

GE Healthcare - Holds 16.3% via strong ECG/imaging systems and integrated cardiac diagnostics solutions in hospitals worldwide.

Siemens Healthineers - Around 17% share backed by advanced imaging, analytical platforms, and troponin test integration.

Beckman Coulter (Danaher) - About 9.6% share with its cardiac marker analyzers and immunoassay systems for troponin testing.

Medtronic - Roughly 21% share in broader cardiovascular diagnostic/monitoring devices (including cardiac monitoring influencing heart attack detection workflows).

Tech & Strategic Partnerships:-

Merge & Us2.ai
Merge (Merative) partnered with Us2.ai to integrate FDA‐cleared AI algorithms into cardiac imaging systems, enabling automatic echocardiogram measurements and enhanced diagnostic reporting.

Fujifilm & Us2.ai
Fujifilm teamed up with Us2.ai to embed AI‐driven automated echocardiography analysis into its LISENDO 800 ultrasound platform - accelerating diagnostic accuracy for chamber/function assessment.

Philips & Myocardial Solutions
Philips collaborated with Myocardial Solutions to advance AI‐enabled cardiac MR imaging, with tools (e.g., Fast‐SENC, MyoStrain) that improve early detection of subtle heart dysfunction relevant to ischemic events.

American College of Cardiology (ACC) & OpenEvidence
Strategic partnership to accelerate translation of AI‐enabled cardiovascular evidence into practice, influencing how diagnostic data (including for myocardial infarction) informs care at the point of service.

SSSIHMS & Siemens Healthineers
Clinical research collaboration between India's SSSIHMS and Siemens Healthineers focusing on advanced echocardiography, automation and early disease detection - a key enabler for improved acute cardiac diagnostics.

HeartBeam & AccurKardia
HeartBeam announced a strategic collaboration with AccurKardia to combine ambulatory ECG hardware with sophisticated ECG analysis software, expanding ambulatory diagnostic capability including acute coronary detection contexts.

📌 Buy Now & Unlock 360° Market Intelligence:https://www.datamintelligence.com/buy-now-page?report=heart-attack-diagnostics-market?prtk

Market Drivers :-

⏩ Heart attacks remain a leading global killer, with cardiovascular diseases (CVDs) causing millions of deaths annually driving urgent demand for early and accurate diagnostics. Healthcare systems are prioritizing tools that identify myocardial infarction swiftly to improve outcomes.

⏩ Rising Prevalence of Lifestyle Risk Factors
Increasing rates of obesity, hypertension, diabetes, and sedentary lifestyles are expanding the pool of at‐risk patients boosting heart attack diagnostic testing frequency worldwide.

⏩ Technological Innovation as a Growth Engine
Advances like high‐sensitivity troponin assays, AI‐based ECG analysis, and portable point‐of‐care devices are shortening time‐to‐diagnosis and improving accuracy critical in emergency settings.

⏩ Shift to Early Detection & Preventive Care
Healthcare strategy is evolving: routine screening, ambulatory ECG monitoring, and non‐invasive imaging are increasing diagnostic touchpoints before acute events occur.

⏩ Expansion of Point‐of‐Care & Decentralized Testing
Portable diagnostics (POCT) in clinics, emergency units, ambulances, and even homes are expanding access and reducing dependency on centralized labs a major efficiency and care‐quality driver.

⏩ Aging Global Population
As populations age, the incidence of coronary diseases rises, pushing demand for specialized cardiac diagnostics suited for older adults with multiple comorbidities.

Regional Insights:-

North America
North America leads the global heart attack diagnostics market, commanding approximately 43% of global market share due to advanced healthcare infrastructure, high adoption of biomarker and imaging diagnostics, and strong reimbursement frameworks.
The U.S. is the dominant contributor, with widespread use of high‐sensitivity troponin tests and ECG systems in emergency care driving robust diagnostic adoption and innovation.

Europe
Europe holds roughly 29% of the market share, supported by universal healthcare systems, extensive screening programs, and investments in point‐of‐care cardiac diagnostics.
Countries like Germany, the UK, and France lead adoption of advanced diagnostic tools, though Eastern European markets continue infrastructure expansion.

Asia Pacific
Asia Pacific accounts for about 23% of the market and is the fastest‐growing region, driven by rising cardiovascular disease prevalence, expanding hospital networks, and improving access to diagnostic technologies in China, India, and Southeast Asia.
Government healthcare investments and increased availability of portable diagnostics are accelerating adoption in rural and urban markets alike.

Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/heart-attack-diagnostics-market?prtk

Market Segmentation :-

By Test:
Electrocardiogram (ECG): Detects abnormal heart rhythms and early signs of heart attack.
Blood Tests: Measures cardiac biomarkers like troponin to confirm heart damage.
Angiogram: Visualizes blocked arteries using contrast dye and X-rays.
Computerized Cardiac Tomography (CCT): Provides detailed 3D heart imaging.
Magnetic Resonance Imaging (MRI): Non-invasive imaging for heart structure and function.
Others: Includes stress tests, echocardiograms, and emerging diagnostic technologies.

By End-User:
Hospitals: Major centers for acute heart attack detection and treatment.
Ambulatory Surgical Centers: Offer diagnostic and minor interventional services.
Diagnostics Centers: Focus on non-invasive tests and routine screenings.
Cardiac Centers: Specialized facilities for cardiovascular care and monitoring.
Others: Includes clinics, research institutions, and mobile diagnostic units.

FAQ'S:-

Q1: What are the common methods for diagnosing a heart attack?
A1: Blood tests, ECG, echocardiogram, and coronary angiography are commonly used.

Q2: Who are the major players in this market?
A2: Key players include Roche, GE Healthcare, Siemens Healthineers, Medtronic, and HeartFlow.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription
Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.